Follistatin-344

Follistatin-344 consists of three follistatin domains plus a C-terminal acidic tail, forming a single polypeptide chain of 344 amino acids. It is heavily glycosylated (covalent attachment of sugar molecules) to improve stability and receptor interactions. Recombinant forms are produced in mammalian cell culture to ensure correct glycosylation patterns and folded structure. Purity and structural integrity are confirmed by size-exclusion chromatography and mass spectrometry.

Follistatin-344 binds with high affinity to myostatin and activins, preventing them from engaging their receptors on muscle and other cell types. This blockade lifts the inhibitory signal on muscle satellite cells (muscle stem cells), promoting muscle growth and regeneration. It also modulates signaling pathways that influence fibrosis (excess tissue scarring) in organs such as liver and kidney. Receptor occupancy and downstream signaling changes are observed in human ex vivo tissue assays.

The peptide is evaluated primarily for treating muscle-wasting conditions and organ fibrosis. In early human studies, follistatin-344 gene therapy increased lean-body mass and muscle strength in patients with muscular dystrophy. Exploratory trials in liver-fibrosis patients reported reduced fibrotic markers and improved liver function tests. Ongoing research is defining optimal delivery methods and long-term effects.

Reported adverse events in initial human studies have included mild injection-site reactions and transient elevations in liver enzymes. No serious cardiovascular or hormonal disturbances have been observed at therapeutic dose levels. Long-term safety data are not yet available, especially regarding off-target effects on other TGF-β ligands. Recommended monitoring includes liver and renal function tests and muscle-function assessments.

Recombinant follistatin-344 is generated in Chinese hamster ovary (CHO) cells using expression vectors carrying the human FS344 gene. Culture supernatant is harvested, and follistatin-344 is purified by affinity and ion-exchange chromatography to research-grade purity. Glycosylation patterns are verified by lectin-binding assays. Final product is sterile-filtered and formulated for injection.

Follistatin-344 is classified for investigational use only and is not approved by the U.S. FDA, EMA, or other major regulators for clinical therapy. It can be administered only under investigational-new-drug (IND) or equivalent protocols. No commercial or over-the-counter formulations exist. Access is limited to approved clinical trials.

Follistatin-344 dosage in early clinical protocols has involved single or repeated intramuscular injections of 1–3 mg of follistatin-344 protein per kilogram of body weight. Some studies deliver the FS344 gene via adeno-associated viral vectors at doses around 1×10¹³ vg/kg. No standardized dosing guidelines exist outside these trials. All administration should follow approved study designs.

• Do restrict use to IRB-approved clinical protocols with vector-safety oversight.
• Do monitor muscle strength, liver enzymes, and renal function.
  ‍
• Don’t combine with other TGF-β pathway modulators without justification.
• Don’t use during pregnancy, lactation, or active malignancy.

• Q: Can follistatin-344 reverse muscle loss?
• A: Early data suggest increased lean-body mass and strength in muscle-wasting patients.
  ‍
• Q: Does it affect reproductive hormones?
• A: No significant changes in sex-hormone levels have been reported.
  ‍
• Q: Is gene therapy delivery safe?
• A: Vector-associated risks are under evaluation, with no serious events in small cohorts.